BR9911357A - Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal - Google Patents

Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal

Info

Publication number
BR9911357A
BR9911357A BR9911357-0A BR9911357A BR9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A
Authority
BR
Brazil
Prior art keywords
fragility
ghs
serm
modulators
selective
Prior art date
Application number
BR9911357-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Producs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Producs Inc filed Critical Pfizer Producs Inc
Publication of BR9911357A publication Critical patent/BR9911357A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9911357-0A 1998-06-16 1999-05-03 Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal BR9911357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16
PCT/IB1999/000796 WO1999065488A1 (fr) 1998-06-16 1999-05-03 Combinaisons therapeutiques de modulateurs (selectifs) des recepteurs des oestrogenes (serm) et de secretagogues d'hormones de croissance (ghs) pour traiter la fragilite musculo-squelettique

Publications (1)

Publication Number Publication Date
BR9911357A true BR9911357A (pt) 2001-03-13

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911357-0A BR9911357A (pt) 1998-06-16 1999-05-03 Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal

Country Status (29)

Country Link
EP (1) EP1085867A1 (fr)
JP (1) JP2002518328A (fr)
KR (1) KR20010052817A (fr)
CN (1) CN1305378A (fr)
AP (1) AP9901581A0 (fr)
AR (1) AR018868A1 (fr)
AU (1) AU3342099A (fr)
BG (1) BG105128A (fr)
BR (1) BR9911357A (fr)
CA (1) CA2335112A1 (fr)
CO (1) CO5070586A1 (fr)
EA (1) EA200001189A1 (fr)
GT (1) GT199900083A (fr)
HR (1) HRP20000857A2 (fr)
HU (1) HUP0102395A2 (fr)
ID (1) ID26726A (fr)
IL (1) IL139587A0 (fr)
IS (1) IS5727A (fr)
MA (1) MA26648A1 (fr)
NO (1) NO20006381D0 (fr)
OA (1) OA11569A (fr)
PA (1) PA8472101A1 (fr)
PE (1) PE20000633A1 (fr)
PL (1) PL345064A1 (fr)
SK (1) SK18902000A3 (fr)
TN (1) TNSN99118A1 (fr)
UY (1) UY25557A1 (fr)
WO (1) WO1999065488A1 (fr)
ZA (1) ZA993973B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (fr) * 1998-08-06 2000-06-07 Pfizer Products Inc. Agonistes/antagonistes de l'estrogène
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
ES2319785T3 (es) * 2001-11-29 2009-05-12 Gtx, Inc. Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
UY25557A1 (es) 2001-01-31
PA8472101A1 (es) 2000-09-29
ID26726A (id) 2001-02-01
EP1085867A1 (fr) 2001-03-28
IS5727A (is) 2000-11-24
WO1999065488A1 (fr) 1999-12-23
PL345064A1 (en) 2001-11-19
TNSN99118A1 (fr) 2005-11-10
EA200001189A1 (ru) 2001-06-25
JP2002518328A (ja) 2002-06-25
PE20000633A1 (es) 2000-07-26
BG105128A (en) 2001-11-30
HUP0102395A2 (hu) 2001-11-28
KR20010052817A (ko) 2001-06-25
AP9901581A0 (en) 1999-06-30
IL139587A0 (en) 2002-02-10
HRP20000857A2 (en) 2001-10-31
NO20006381L (no) 2000-12-14
OA11569A (en) 2004-07-01
CN1305378A (zh) 2001-07-25
MA26648A1 (fr) 2004-12-20
CA2335112A1 (fr) 1999-12-23
AU3342099A (en) 2000-01-05
AR018868A1 (es) 2001-12-12
NO20006381D0 (no) 2000-12-14
ZA993973B (en) 2000-12-15
SK18902000A3 (sk) 2001-12-03
CO5070586A1 (es) 2001-08-28
GT199900083A (es) 2000-12-05

Similar Documents

Publication Publication Date Title
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EE04018B1 (et) Tieno[2,3-d]pürimidiindioonid, nende valmistamisemeetod ja neid sisaldavad ravimkoostised
AU6422399A (en) 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
PT1222195E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
HUP0402270A2 (hu) [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
BR0100558A (pt) Composições e métodos para tratar a osteoporose
NO993027D0 (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
BR9911357A (pt) Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal
CA2325842A1 (fr) Methodes de production et d'administration de preparations combinant un antagoniste de rho et un adhesif tissulaire aux systemes nerveux central et peripherique blesses de mammiferes et utilisations de ces preparations
BR9911228A (pt) Combinações terapêuticas compreendendo um modulador seletivo de um receptor de estrogênio e hormÈnio paratireóide
BR9911324A (pt) Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal
BRPI0418887A (pt) nucleosìdeos de 3-beta-d-ribofuranossiltiazol[4,5-d] pirimidina e usos dos mesmos
BR0112619A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, métodos para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e de distúrbios no sistema nervoso central e/ou de bexiga hiperativa ou vasospasmo ou para o controle do crescimento de tumores
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
CA2274381A1 (fr) Combinaisons therapeutiques comprenant de la prostaglandine et un modulateur selectif de recepteur oestrogenique
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
TH57984A3 (th) การรวมในทางการรักษาซี่งประกอบด้วยตัวปรับตัวรับเอสโตรเจนแบบคัดเลือกและฮอร์โมนพาราไธรอยด์
TH48282A (th) การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]